NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Evaluate:Thanks for the clarification.A.E.K.

ae kusterer Saturday, 01/22/22 08:50:56 PM
Re: None 0
Post # of 437833
Is it safe to assume this has no credibilty with the FDA?

"A phase 3 clinical study ... found that the DCVax®-L drug was feasible and safe in adult patients. Furthermore, this treatment strategy is likely to prolong progression-free and overall survival..."

The $NWBO #DCVax® Platform for All Solid Tumor Cancershttps://t.co/Y7gKlc2SIV pic.twitter.com/8TPq5Js32x

— rj (@sharpie510) January 22, 2022

Evaluate Member Level Saturday, 01/22/22 09:41:50 PM
Re: None 0
Post # of 437833
Chinese Neurosurgical Journal - Glioblastoma vaccine tumor therapy research progress
Published: 19 January 2022

Tong Zhao, Chunwang Li, Hongliang Ge, Yuanxiang Lin & Dezhi Kang
Chinese Neurosurgical Journal volume 8, Article number: 2 (2022)
includes:
Quote:
Dendritic cell vaccine
The treatment of GBM vaccine clinical trials currently under way is the most clinically available DC vaccine clinical trial.
DCs are the strongest antigen-presenting cells in humans; they induce innate immunity, acquired immunity, and enable immunity conversion. In addition, they also influence the immune responses of lymphocytes, differentiation, and antigen presentation [17].
DCs were discovered by Steinman in 1973; however, its key role in the immune response were established only in the early 1990s [18].
DC vaccine preparation and inoculation involves isolating the DCs from the patient, loading them with tumor antigens and treating them with the corresponding cytokines to induce maturity, and finally the preparation of human DC vaccines for re-injection into the patient [19].
This DC vaccine preparation process is a reasonable anti-tumor vaccine strategy, majorly because it formed the main body of silence-T; it is the first FDA-approved cancer vaccine. Sepulture-T is demonstrated to be clinically efficient in improving the median overall survival period in prostate cancer patients of 4 months [20]. For treating GBM with DC vaccine, DCs are isolated from the peripheral blood CD-14 positive monocytes and GM-CSF and IL-4 are used to induce the differentiation of immature DCs [21].
The tumor antigens (including polypeptide, RNA, DNA, and tumor lysates) are loaded into the immature DCs, which are then presented on MHCs, and the various cytokines (for example, of GM-CSF, of IL-.4, of TNF-a, and IL-6 under) action to maturity [21, 22].
The USA, Europe, and Japan have published a lot of respect for the use of DC vaccine therapy in glioma clinical research paper [23].
The Department of Neurosurgery in our hospital is also actively conducting a phase II clinical trial of a DC vaccine and found that the DC vaccine marginally improves the survival period of GBM patients [24].
However, there is still no clear evidence for testing the efficacy in a phase III clinical trial, and the production of vaccines is very expensive.
Diva is a DC vaccine project developed by Northwest Biotherapeutics based on the research of Linda Lieu et al. [25]; it is presently in phase III clinical trials.
The latest developments in DC vaccines include the pretreatment of vaccine sites. Dendritic cells carrying cytomegalovirus phosphoprotein 65 (pp65) RNA significantly improve lymph node homing and prolong the overall survival time, following the pretreatment of the vaccine site with tetanus/diphtheria antigens [26].


https://cnjournal.biomedcentral.com/articles/10.1186/s41016-021-00269-7


iwasadiver Member Level Saturday, 01/22/22 09:08:23 PM
Re: ae kusterer post# 437828 0
Post # of 437833
What do you mean “credibility”? It’s a book for professionals.

PREFACE
Frontiers in Clinical Drug Research - Anti-Cancer Agents presents recent developments in various therapeutic approaches against different types of cancer. The book is a valuable resource for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti- cancer research. The chapters are written by authorities in the field. The contents of this volume represent exciting recent researches on Acute Myeloid Leukemia, Chemotherapy, Gastrointestinal Cancer, Anti-cancer Therapy, Breast Cancer Cells, and Lung Cancer. I hope that the readers will find these reviews valuable and thought provoking so that they may trigger further research in the quest for the new and novel therapies against cancers.
I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications), and Mr. Shehzad Naqvi (Editorial Manager Publications) at Bentham Science Publishers.
Atta-ur-Rahman, FRS Honorary Life Fellow Kings College University of Cambridge UK
i